7
Total investments
1
Early stage
2
Mid stage
2
Late stage
17y
Years active
Portfolio
6 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Jul 2025
Fellow is the only peer-reviewed, clinical semen analysis your patients can do from home.
Fellows solutions include: Full Semen Analysis, Post-Vasectomy Semen Analysis , and Cryopreservation.
www.meetfellow.com
Board Member
Jun 2014
G-CON Manufacturing, Inc.’s prefabricated, turnkey cleanroom systems represent a significant transition to forward thinking in pharmaceutical and biopharmaceutical processing. G-CON Manufacturing, the innovator of autonomous cleanroom PODs, turned the challenges experienced by the biopharmaceutical industry into readily deployable, flexible, mobile and scalable cleanroom solutions. PODs are ideal for multi-product sites, rigorous containment needs, and on demand scaling of production and laboratory space.
Building on its first design in 2009, G-CON now has a wide array of cleanroom PODs in their product portfolio to accommodate the increased demand from the pharmaceutical, biopharmaceutical and cell therapeutic industries. Moreover, G-CON’s patent portfolio continues to grow which will effectively preclude imitators from copying G-CON’s initial and more recent innovations.
At G-CON, we will continue to evolve and grow with the industry to provide a comprehensive cleanroom solution that truly is flexible, scalable and fast, all for a fair and known price from the time the contract is signed.
Board Member
Mar 2014
SCINTIX biology-guided radiotherapy now FDA cleared.
SCINTIX™ therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
Board Member
Oct 2013
BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop new small molecule therapeutics against challenging, high-value drug targets.
Board Member
Aug 2009
We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer.
Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, Novocure has offices in Germany, Jersey, Japan and Israel.
Experience · 10 entries
All (10)
Investments (7)
Board (7)
2025
Board Member
Jul 2025
Fellow is the only peer-reviewed, clinical semen analysis your patients can do from home.
Fellows solutions include: Full Semen Analysis, Post-Vasectomy Semen Analysis , and Cryopreservation.
www.meetfellow.com
2023
Managing Partner, Life Sciences
Nov 2023
The Forest Road Company is a next-generation merchant bank that invests, operates, and advises in non-correlated yet highly transformative sectors.
Disclosures: forestroadco.com/socialmedia
2021
Managing Partner, Life Science & Healthcare, SVB Capital
Feb 2021
Silicon Valley Bank (SVB), a division of First Citizens Bank, is the bank of the world’s most innovative companies and investors. SVB provides commercial and private banking to individuals and companies in the technology, life science and healthcare, private equity, venture capital and premium wine industries. SVB operates in centers of innovation throughout the United States, serving the unique needs of its dynamic clients with deep sector expertise, insights and connections. SVBs parent company, First Citizens Bancshares, Inc. (NASDAQ: FCNCA) is a top 20 U.S. financial institution with more than $200 billion in assets. First Citizens Bank, Member FDIC. Learn more at svb.com.
Please contact client service at https://www.svb.com/client-service/help-desk/ for all account questions. To ensure your information is secure, please do not include any personal account information in posts or messages.
Please visit https://jobs.firstcitizens.com/ if you are interested in a career at SVB.
Comments are moderated and will be removed if they are off-topic or abusive.
Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as well as the other divisions, subsidiaries, and affiliates of First-Citizens Bank & Trust Company (together, SVB), are U.S. financial institutions and provide products and services to non-U.S. clients on a cross-border basis from the United States of America. SVB is not licensed or regulated as a bank or any other type of financial institution outside of the United States of America. Please review our International Disclosures for more information: https://www.svb.com/international-disclosures/
2014
Board Member
Jun 2014
G-CON Manufacturing, Inc.’s prefabricated, turnkey cleanroom systems represent a significant transition to forward thinking in pharmaceutical and biopharmaceutical processing. G-CON Manufacturing, the innovator of autonomous cleanroom PODs, turned the challenges experienced by the biopharmaceutical industry into readily deployable, flexible, mobile and scalable cleanroom solutions. PODs are ideal for multi-product sites, rigorous containment needs, and on demand scaling of production and laboratory space.
Building on its first design in 2009, G-CON now has a wide array of cleanroom PODs in their product portfolio to accommodate the increased demand from the pharmaceutical, biopharmaceutical and cell therapeutic industries. Moreover, G-CON’s patent portfolio continues to grow which will effectively preclude imitators from copying G-CON’s initial and more recent innovations.
At G-CON, we will continue to evolve and grow with the industry to provide a comprehensive cleanroom solution that truly is flexible, scalable and fast, all for a fair and known price from the time the contract is signed.
N
NeuMoDx Molecular
Board Member
Mar 2014
Show all 10 entries ↓
Investment activity
2009–2025 · 7 investments
Recent (last 2 years)Earlier
